Abdullah ALTINTAS ; Orhan AYYILDIZ ; A Engin ATAY ; Timucin CIL ; Abdurrahman ISIKDOGAN ; Ekrem MUFTUOGLU
Annals of the Academy of Medicine, Singapore 2007;36(4):304-306
Angiogenesis Inhibitors ; administration & dosage ; adverse effects ; Humans ; Male ; Middle Aged ; Multiple Myeloma ; drug therapy ; Risk Factors ; Thalidomide ; administration & dosage ; adverse effects ; Thromboembolism ; chemically induced ; diagnosis